What are the opening hours?

Monday 08:00 - 18:00 Tuesday 08:00 - 18:00 Wednesday 08:00 - 18:00 Thursday 08:00 - 18:00 Friday 08:00 - 18:00 Saturday 08:00 - 18:00 Sunday 08:00 - 18:00

Pacclinic International Hospital, 4F Pacclinic Building, Kunming-Bangkok Avenue, Boten, Muong Boten (2026)

02/12/2025

2025年12月2日，CIBC中以汇达董事总经理、太诊国际医院董事长、台湾新北太诊IVF中心(TWIVF)董事董寿伟博士受台湾大健康产业联盟协会王国安理事长邀请，出席了在上海举办的第一届两岸生命科学产业技术合作大会暨两岸大健康产业企业家俱乐部成立大会并做发言。

董寿伟博士在核心组会议中与原上海东方医院院长刘中民教授、王国安理事长做了AI赋能两岸生物医疗产业创新技术发展的面对面交流和发言。

05/10/2025

Q&A Interactive｜Pacclinic International Hospital Explains How Boten SEZ, Laos Created a “Due Diligence Closed Loop” to Form a Perfect Investment Scam

After Caixin.com published its August 8, 2025 investigative report titled “13 Chinese Private Medical Institutions Fail in Laos Economic Zones”, many concerned clients, journalists, and members of the public left comments and messages on Pacclinic International Hospital’s media platforms, asking why investors had not conducted proper due diligence before investing in Boten, Laos.

Response from Boten Pacclinic International Hospital (PACCLINIC):

According to Caixin’s 2025 investigation, from 2019 to 2024, a total of 13 Chinese private medical institutions invested in the China-Laos Cooperation Zone’s Boten Special Economic Zone (SEZ). These included entities backed by publicly listed companies and well-known medical groups in China. Most focused on high-end medical services such as assisted reproduction, stem cell therapy, and wellness centers.
However, Boten SEZ deliberately concealed a critical legal fact: assisted reproductive (IVF) services are prohibited by Lao national law for private enterprises. Although the SEZ claimed to have applied for special approval from the Lao National Assembly, those applications were never approved. As a result, nearly all of the more than ten Chinese companies failed — projects were suspended, withdrawn, or bankrupted — leading to cumulative investment losses of several billion RMB.
Conducting due diligence is a necessary step for every investor, yet the Boten SEZ created a “due diligence closed loop” — a perfect deception system — that made real verification impossible.
(1) Using Government Filing and “China-Laos Cooperation Zone” to Mask Reality
Yunnan Haicheng Group, as the sole developer and investment promoter of the Boten SEZ, completed its overseas investment filing in China (approved by the Yunnan Provincial Department of Commerce, Development and Reform Commission, and the State Administration of Foreign Exchange). It then established Laos Boten Economic Zone Development Group Co., Ltd. abroad, forming an appearance of “legality and compliance.”
Its chairman, Zhou Kun, was even appointed by the Lao side as “Chairman of the Boten Government” and publicly claimed that “Boten is managed by Chinese people.” In promotional materials, the group repeatedly blurred its relationship with the China-Laos Mohan–Boten Economic Cooperation Zone Administrative Committee, a legitimate Chinese government institution, thus creating a false image of official Chinese government backing that misled investors.
(2) Bringing in a Hong Kong–Listed Company for Authority and Credibility
In 2019, Boten SEZ successfully introduced two assisted reproduction medical institutions, one of which was Ruiya International Medical Center.
On March 3, 2020, Hong Kong–listed company Jinxin Fertility Group (HK1951) announced that on February 29, 2020, it had agreed to acquire from Ruiya International Medical Center certain licenses to provide assisted reproductive services and operate an IVF clinic in the Boten SEZ. The clinic, covering approximately 5,000 square meters, was expected to open in the third quarter of 2020 and offer IVF-ET, ICSI, PGS/PGD, third-party IVF services, and gamete cryopreservation.
In its 2020 annual report (released in early 2021) and even in its 2024 annual report (released in early 2025), Jinxin Fertility continued to highlight the Laos project (Jinrui International Medical Center) as a contributor to overseas revenue growth.
However, in the mid-2025 interim report, Jinxin briefly stated:
“The Group’s business in Laos has been impaired due to increased policy uncertainty in the Lao IVF sector. The Group has therefore decided to terminate operations at Jinrui Medical Center in Laos.”
As a publicly listed company, Jinxin Fertility has a fundamental responsibility to protect investors and set an industry standard. Yet its earlier “successful Boten case,” publicized through official channels, was used by Yunnan Haicheng Group to report to the Yunnan Provincial Health Commission as part of its “Boten Medical Industry Plan,” thereby creating a false perception of Chinese official endorsement.
This false endorsement led many to believe the Boten medical projects were legal and compliant, paving the way for broader fraudulent investment recruitment.
(3) Using Pacclinic International Hospital as the Model Case
During the investment promotion campaign, the Boten SEZ Management Committee repeatedly showcased Pacclinic International Hospital (funded by an overseas Chinese enterprise from Shanghai) — a facility with advanced “ovarian stem cell + IVF” biomedical technology — as a model international hospital.
The Committee even submitted Pacclinic’s case to the Yunnan Provincial Department of Commerce as proof of successful investment.
In 2022, the Yunnan Provincial Department of Commerce issued the Investment Cooperation Guide for the China-Laos Mohan–Boten Economic Cooperation Zone, which was later presented at the China-Laos joint investment promotion event during the 2022 China International Import Expo in Shanghai — further strengthening the illusion of “official endorsement.”
Yunnan Haicheng Group displayed this government-issued guide in the lobby of the Boten SEZ Management Office as “national-level certification.”
Following the earlier cases of the Lao International Reproductive Genetics Hospital and Jinxin Fertility’s Jinrui International Medical Center, Pacclinic became the third actual reproductive hospital established in Boten, and the combination of a listed company (Jinxin Fertility) + a Yunnan provincial government–promoted project (Pacclinic) became a dual-layer endorsement, luring over ten subsequent investors into the trap.
(4) Creating the “Due Diligence Closed Loop” — The Perfect Scam
During Pacclinic’s own investment due diligence, the Boten SEZ Management Committee and related personnel deliberately built an information “island” to ensure investors saw only what they wanted them to see:
Visible Success Stories: Existing hospitals (including a Hong Kong–listed company’s project) were presented as “proof” that the medical industry had already taken root.
Government Documents as Support: Official-looking materials — such as the Investment Cooperation Guideissued by the Yunnan Department of Commerce — were displayed as “policy basis” to increase credibility.
Chinese Management Narrative: The SEZ’s Chinese staff and affiliated media repeatedly claimed “Boten is managed by Chinese people,” easing investors’ concerns about foreign control.
Information Asymmetry: When conducting due diligence in Vientiane, investors were told that Boten’s business registry was not connected to Laos’ national registration system because “the SEZ has autonomy and independent investment authority.”
Official Reconfirmation: Even when Dr. D**g Shouwei later petitioned, the Yunnan Department of Commerce replied that “Boten SEZ investment policies are independently determined by the Management Committee and Yunnan Haicheng Group.”

This interlocking chain of false information trapped investors in a seemingly legitimate but actually fabricated environment — eliminating any ability to independently assess risk.

Consequently, over a dozen Chinese enterprises entered Boten at different times and in different forms — yet none escaped losses. This clearly demonstrates that the Boten investment promotion campaign was, in essence, a systemic and deceptive operation.

Taiwan Newtalk News reported

05/10/2025

《提问互动｜太诊国际医院详述老挝磨丁投资设置尽调闭环、形成完美骗局》

在2025年8月8日财新网发布调查报道《13家中资民营医疗机构折戟老挝经济特区》后，近期，热心客户和媒体人等社会公众人士在太诊国际医院各自媒体平台后台留言询问，为什么当初投资老挝磨丁前没有做好投资尽调工作。

磨丁太诊国际医院（PACCLINIC）回答：

据财新网2025年调查报道，自2019年至2024年间，共有13家中资民营医疗机构进入中老合作区老挝磨丁特区投资，其中包括上市公司背景的机构和在国内具有较高知名度的医疗集团。这些企业大多涉及高端医疗服务，如辅助生殖、干细胞临床应用、康养中心等。然而，因磨丁特区在招商宣传中故意隐瞒辅助生殖试管婴儿医疗服务属于老挝国家法律禁止私营企业从业的事实，且特区上报老挝国会的相关申请并未获批，最终十多家中资企业几乎全部折戟沉沙，项目停摆、撤退、破产，投资损失累计数十亿元人民币。

投资之前的尽调是每一个企业都会做的必要工作，然而老挝磨丁经济特区对投资设置“尽调闭环”、形成了完美的骗局。

具体表现为：
（一）利用备案身份与“中老合作区”掩护
云南海诚集团作为磨丁经济特区的管理和招商唯一主体，其在中国境内完成了境外投资备案（由云南省商务厅、发改委、外管局核准），在境外设立了老挝磨丁经济特区开发集团有限公司，形成了“合法合规”的表象。

其董事长周昆更被老挝方面任命为“磨丁政府主席”，并对外宣称磨丁经济特区“由中国人管理”。在招商宣传中，该集团频繁擦边由云南省政府设置的政府机构“中国老挝磨憨—磨丁经济合作区管委会”，模糊其与中国政府的关系，制造“官方背景”假象，极大地麻痹投资者。

（二）引入港股上市公司与权威背书
2019年，磨丁特区成功引入两家辅助生殖医疗机构，其中之一瑞亚国际医学中心。

2020年3月3日香港上市公司锦欣生殖（HK1951）发布公告，宣布于2020年2月29日同意自第三方瑞亚国际医学中心收购相关经营许可，于老挝磨丁经济特区提供辅助生殖服务及经营IVF（体外受精）诊所，面积约为5000平方米，预计2020年第三季度开业，提供IVF-ET（体外受精及胚胎移植）、ICSI（卵细胞浆内单精子注射）、PGS（植入前基因筛查）/PGD（植入前遗传学诊断）、第三方IVF，各种IVF技术及治疗选择及卵子及精子冷冻保存。

其后2021年初发布的2020年报，直到今年年初即2025年年初发布的2024年年报的公告还提及了老挝业务（锦瑞国际医学中心）为2024全年海外业务增长做出了贡献。

但在2025年9月最近发布的2025年中报中，简单地提及“本集团于老挝的业务出现减值，是由于老挝IVF行业政策的不确定性增加，因此本集团决定终止锦瑞医学中心于老挝的业务。

上市公司的基本责任是为投资人负责、为行业树立典范。基于此原则，上市公司锦欣生殖HK1951的“磨丁成功案例”，被官网媒体报道。云南海诚集团就此曾亲赴云南省卫健委汇报磨丁医疗产业规划，从而在业界营造出“磨丁医疗产业已获得中国官方认可”的氛围。此举使外界形成了磨丁医疗项目合法化、合规化的初步认知，为其后续大规模招商奠定了虚假背书。

（三）以磨丁太诊国际医院为招商样板
磨丁特区管委会在招商过程中，将拥有先进“卵巢干细胞+IVF试管婴儿”组合方案生物医疗技术的上海以侨企业投资的“磨丁太诊国际医院”作为典型案例反复宣传，称其为“国际知名医疗机构”，并向云南省商务厅提供相关成功案例材料。

2022年，云南省商务厅基于此印发了《中国老挝磨憨—磨丁经济合作区招商专案投资合作指南》，并在2022年上海进博会云南省政府系列主题活动的中老合作区联合招商会上引用，进一步强化了“官方认证”的效果。

云南海诚集团在老挝磨丁管委会大厅中展示该招商指南，以此作为“国家级背书”。磨丁太诊国际医院成为自老挝国际生殖遗传专科医院、锦欣生殖旗下锦瑞国际医学中心后老挝磨丁特区实际意义第三家成功落地的生殖医院后，“上市公司锦欣生殖的医院➕云南省政府招商太诊医院”的组合成为了磨丁招商的叠加背书，进一步欺骗后续其他十余家投资人跟进入坑。

（四）设置“尽调闭环”，形成完美骗局
在Pacclinic太诊国际医院投资人实地尽调过程中，老挝磨丁管委会和相关人员刻意设置了信息孤岛：
现场可见案例：磨丁已有医院（包括港股上市公司项目）作为“成功样板”，证明医疗产业“确已落地”；
政府文件支撑：在老挝磨丁特区一站式大厅放置云南省商务厅印发的招商指南作为政策依据，增加公信力；
中国人管理：云南海诚集团招商局及授意的自媒体公开宣称“磨丁由中国人管理”，消除投资人对外资管控的顾虑；
信息不对称：在老挝万象尽调时，投资人被告知磨丁企业工商系统不联网，不在国家登记系统中，理由是“特区自治、招商自主”；
官方背书再确认：云南省商务厅在董寿伟博士信访时亦答复称“磨丁特区招商政策由管委会、云南海诚集团自主决定”。

这一套环环相扣的虚假信息链条，使投资人被彻底锁定在一个看似真实、实则虚假的闭环中，失去了独立判断风险的可能性。

正因如此，后面十余家家企业在不同时间、不同地方进入磨丁，最终却无一幸免，集体陷入损失。这已充分说明磨丁招商宣传本质上存在系统性欺骗性操作。

来源：台湾Newtalk新闻

21/09/2025

台湾Newtalk新闻2025年9月21日报道：

19日，一封特殊的挂号信通过中华邮政自中国台湾地区寄出。寄信地址为台北市中山区八德路二段232号，收件人为大陆云南省昆明市云南省人民政府省长王予波。

据了解，该台湾宗亲长辈的信件系关于大陆台属董寿伟先生在中老合作区投资磨丁太诊国际医院的“信访”材料。董寿伟先生曾经响应大陆云南省政府的招商引资政策，赴中老合作区投资医疗项目。然而，该项目在发展过程中遭遇波折。今年8月，中国财新网曾在报道《13家中资民营医疗机构折戟老挝经济特区》中将此作为典型案例予以披露。

事件不仅关乎董寿伟先生及其家人的切身利益，也引起两岸企业界和社会各界的高度关注。董寿伟先生作为大陆台属，其投资行动本意在于积极响应“一带一路”倡议，推动中老合作区医疗事业发展，彰显两岸一家亲的情感纽带。如今因投资受挫引发信访，反映出相关问题的复杂性和敏感性。

跨海峡信访，意味着事件进入新的舆论与政治关注阶段。两岸舆论普遍认为，此事不仅涉及个人权益的保障，更事关台胞台属对中国国家政策信任的巩固与信心，影响“一带一路”背景下的跨境合作氛围。

目前，社会各界正在关注云南省政府及相关部门对该事件的动态处置和后续回应。

来源：台湾NEWTALK新闻

11/07/2025

中国投资人董寿伟博士致老挝人民革命党中央总书记、国家主席通伦·西苏里阁下的信
Letter from Chinese investor Dr. D**g Shouwei to His Excellency Thongloun Sisoulith, General Secretary of the Central Committee of the Lao People's Revolutionary Party and President of Laos

Your Excellency Mr. Thongloun Sisoulith,

President of the Lao People's Democratic Republic,

It is with immense excitement and profound reverence that I address this letter to you. To express my utmost respect and to articulate my thoughts with greater clarity, I have chosen to write in English, the international language I am most proficient in.

My name is D**g Shouwei. I was born in Shanghai, China, and am a researcher and scientist specializing in assisted reproductive medical technology. In my early years, I completed my Bachelor's, Master's, and Doctoral studies in Biophysics in Germany, participating in the research and development of specialized materials for the European Space Agency. In 2011, I served as the Deputy Editor-in-Chief for the Chinese national engineering machinery industry reference book, "China Road Construction and Maintenance Machinery Equipment Manual," and was the primary inventor of an inclinometer sensor. I also led the R&D for the fully automated manufacturing technology of micro-manipulation needles used in IVF (In Vitro Fertilization), filling a technological gap within China. These achievements have been recognized by the Chinese People's Political Consultative Conference (CPPCC), and relevant information can be found in my Baidu Baike (Baidu Encyclopedia) entry under "董寿伟" (D**g Shouwei).

Beyond my scientific work, I actively participate in public affairs, currently serving as a member of the Putuo District Committee of the CPPCC in Shanghai and as a member of the Healthcare and Sports Committee of the Shanghai Municipal Committee of the Revolutionary Committee of the Chinese Kuomintang (RCCK), among other roles.

In November 2022, I was invited to attend the China-Laos Mohan-Boten Economic Cooperation Zone Joint Investment Promotion Conference, hosted by the People's Government of Yunnan Province, China, during the Shanghai China International Import Expo. At the event, where Governor Wang Yubo of Yunnan Province delivered a speech, I was received by Mr. Li Chenyang, then Director-General of the Yunnan Provincial Department of Commerce. After reviewing the investment promotion policies for assisted reproductive medicine in Boten, Laos, issued by the Yunnan Department of Commerce, I initiated contact with the Boten Economic Special Zone Investment Promotion Bureau. In 2023, I formally signed a contract with the Boten Economic Zone Development Group Co., Ltd. (a wholly-owned subsidiary of Yunnan Hai Cheng Group), submitted my investment application to the Boten Special Economic Zone Administrative Committee Government, Luang Namtha Province, Laos, and successfully registered the Boten Pacclinic International Hospital. The hospital's core business scope encompasses assisted reproduction, stem cells, and clinical medical research.

From that point forward, my vision has been to dedicate my life's work, particularly my achievements in IVF micro-manipulation technology, to advancing medical technology in Laos. I am committed to establishing the Boten Pacclinic International Hospital project as a pinnacle of China-Laos cooperation under the Belt and Road Initiative. Furthermore, I aim to train and employ graduates from Lao medical universities in assisted reproductive technologies and collaborate closely with Lao health authorities to elevate the overall standard of healthcare in Laos. To this end, under my initiative, we established the Laos-China Medical Services Industry Association in Boten, Laos, in July 2024.

Human Assisted Reproductive Technology (ART), primarily referring to IVF, involves extracting s***m from the male partner and eggs from the female partner. These are then combined in a laboratory setting under specialized microscopes for fertilization. The resulting embryos are cultured in specific equipment. Utilizing advanced Preimplantation Genetic Testing (PGT), embryos with chromosomal abnormalities or genetic diseases are screened out, allowing the selection of healthy embryos for transfer back into the female's uterus for implantation and pregnancy. This is a high-end medical technology crucial for improving population quality, enabling healthy births, and safeguarding the health of women and children.

Significantly, this technology is not limited to humans; it also has vital applications in breeding high-quality dairy cattle, agricultural livestock, and endangered species. Boten Pacclinic International Hospital is willing to transfer this technology to Lao medical and livestock industry counterparts free of charge.

Our project is listed on the official Chinese Belt and Road portal and has received support from multiple Chinese government departments.

However, since October of last year, our aspirations in Boten, Laos, have suffered a severe setback.

**Boten Pacclinic International Hospital Application Process & Current Status:**

1. **Investment Promotion Phase (2022):** Attended Yunnan Provincial Gov't Investment Conference at Shanghai Import Expo; Received Gov't Promotion Handbook (**Explicitly Permitted** ART services).

2. **Case Studies Visited (2023):** Visited operational "Lao Genetics & Reproductive Specialist Hospital" in Boten (est. 2019) and Jinrui Boten reproductive center acquired by a HK listed company (in 2020） (**Both Operational**).

3. **Formal Contract Signing (2023):** Signed investment contract with Boten Economic Zone Development Group Co., Ltd. (**Contract Permitted** ART services).

4. **Pre-Investment Review (2023):** Submitted complete project documents (business plan, feasibility report, resumes, agreements) to Lao authorities (Luang Namtha Province Gov't, Boten SEZ Admin Committee, National Planning & Investment Dept.) per Lao Enterprise Law & Foreign Investment Promotion Law (**Review Approved**).

5. **Enterprise Establishment (2023):** Obtained Enterprise Registration Certificate & Tax Registration Certificate from MPI and Boten SEZ Admin Committee (**Certificates Explicitly Include** ART/IVF medical services, hospital operations, etc. - 6 items total).

6. **Trial Operation Permission (2024):** Granted permission by Boten SEZ Admin Committee & Investment Bureau to conduct trial operations for ART/IVF and stem cell medical services (**Explicit Permission Granted**).

7. **Problem Exposure (Oct 2024 - May 2025):** By May 2025, Boten IPB had attracted 13 ART/Stem Cell hospitals (Chinese, US, etc.). Lao Ministry of Public Security raided and sealed 5 of these hospitals in Oct 2024 and Apr 2025, confiscating equipment, detaining staff, etc(Pacclinic was NOT raided). This exposed serious irregularities in Boten's investment promotion (**Revealing de facto prohibition of ART services**).

8. **Operation Halted (2025):** Upon clarification: Despite prior investment approval and valid certificates, per Lao Medical Law, Guidelines for Establishing Private Hospitals, and Agreement on Surrogacy and Abortion Management, the Ministry of Health (MoH) prohibits private hospitals from providing ART/IVF services and refuses to issue the required medical practice license (**Operation Confirmed Impossible**).

To safeguard Laos's reputation as an international investment destination, I wrote to Mr. Bakhodir Burkhanov, the UN Resident Coordinator in Laos, in January of this year. He replied twice, confirming that the matter was referred to relevant central government departments in Laos. Concurrently, I have actively communicated with over a dozen Chinese entities, including the Chinese Embassy in Laos, the Ministry of Commerce, the Ministry of Foreign Affairs, the People's Governments of Yunnan Province and Shanghai Municipality, seeking their assistance in coordination.

On May 20, 2025, arranged by the Chinese Embassy in Laos, I met with Mr. Khamsay, Director-General of the Department of Healthcare and Rehabilitation, Lao Ministry of Health. While expressing sympathy for my situation, he clearly stated that although Boten Pacclinic Hospital had passed the investment review and legally obtained Enterprise and Tax Registration Certificates explicitly including ART/IVF medical services, he could not issue the medical practice license for ART/IVF to our private hospital under the current regulations of the MoH.

Your Excellency, as my background illustrates, I am not merely a businessman but a scientist in biomedical technology. I came to invest in Laos with the most sincere aspiration to foster collaboration and exchange in biomedical technology between China and Laos. I firmly believe Laos is undergoing a stage similar to the early days of China's Reform and Opening-up. Innovative endeavors beneficial to technological progress and national well-being often face initial skepticism. However, guided by your exceptional wisdom and foresight, any difficulty can be overcome. Under your leadership, the Lao government and people are achieving daily progress in technological and organizational innovation. You are the sun illuminating Laos's path of development.

I earnestly appeal for your attention and support regarding this matter. I am deeply committed to staying in this beautiful land of Laos and contributing to its development in the field of biomedical technology. May the friendship between Laos and China endure forever.

I look forward to your response. Thank you most sincerely for your valuable time.

Respectfully Yours,

Your Sincere International Collaborator,

D**g Shouwei

July 07, 2025

中文译文：

《中国投资人董寿伟博士致老挝人民革命党中央总书记、国家主席通伦·西苏里阁下的信》

敬爱的通伦·西苏里主席阁下：

怀着无比激动与崇敬的心情，我谨致信于您。为表达我对您的最高敬意，并更清晰地阐述我的想法，我选择使用我所掌握的最为熟练的国际语言——英文来撰写此信。

我是董寿伟，出生于中国上海，是一名专注于辅助生殖医疗科技的研究者与科学家。早年我在德国完成了生物物理学本科、硕士及博士学业，并参与了欧洲宇航局多项特殊材料的研发工作。2011年，我担任中国国家工程机械行业工具书《中国筑养路机械设备手册》副主编，同时是一种倾角传感器的第一发明人。我还主导了辅助生殖行业试管婴儿显微操作针全自动化制造技术的研发，填补了该技术在国内的空白。这些成就获得了中国政协组织的认可，相关信息可在百度百科“董寿伟”词条中查询。

除科研工作外，我也积极参与社会事务，现任上海市普陀区政协委员、民革上海市委会医卫体委员等职。

2022年11月，我受邀参加中国云南省人民政府在上海进博会期间主办的中国老挝磨憨-磨丁经济合作区联合招商会。会上，云南省王予波省长发表致辞，我有幸得到时任云南省商务厅厅长李晨阳先生的接待。在获悉云南省商务厅印发的关于老挝磨丁辅助生殖医疗招商政策后，我随即与老挝磨丁经济特区招商局对接。2023年，我正式与老挝磨丁经济专区开发集团有限公司签约，并向老挝琅南塔省磨丁经济特区政府提交了投资申请，成功注册了以辅助生殖、干细胞及临床医学研究为主营业务的磨丁太诊国际医院。

自此，我的愿景是运用毕生所学，特别是在试管婴儿显微操作技术研发领域的成果，服务于老挝医疗技术水平的提升。我致力于将磨丁太诊国际医院项目打造成为中老“一带一路”合作的典范，同时培养和吸纳老挝医科大学毕业生学习辅助生殖技术，并与老挝卫生部门通力合作，提升老挝整体医疗卫生水平。为此，在我的推动下，我们于2024年7月在老挝磨丁成立了老挝中华医疗服务业联合会。

人类辅助生殖技术（主要指试管婴儿技术），其核心流程是：将夫妇双方的精子和卵子分别取出，在实验室器皿中，由专业医疗人员在特殊显微镜下操作完成体外受精；受精卵在特定设备中培养成胚胎后，通过植入前遗传学诊断技术筛选染色体正常、无遗传疾病的优质胚胎，再将其移植回女方子宫内着床妊娠。这是一项旨在提高人口质量、实现优生优育、保障妇女儿童健康的高端医疗技术。

值得强调的是，此项技术不仅应用于人类生殖，亦可广泛应用于优质奶牛、农业牲畜及珍稀动物的繁殖。磨丁太诊国际医院愿无偿将此技术传授给老挝的医疗和畜牧业同行。

我们的项目已登陆中国官方的“一带一路”网，并得到了中国多个政府部门的支持。

然而，自去年10月起，我们在老挝磨丁的美好愿景遭遇了重大挫折。

**磨丁太诊国际医院申办流程与现状：**

1. **招商阶段 (2022年)：** 参加云南省政府于上海进博会主办的招商会；获得云南省政府招商政策手册（**明确允许**从事辅助生殖医疗服务）。

2. **考察案例 (2023年)：** 参观磨丁当地已开业的“老挝遗传生殖专科医院”（2019年开业）及某上市公司2020年公告收购的磨丁生殖中心（**均在运营**）。

3. **正式签约 (2023年)：** 与云南海诚集团全资子公司“老挝磨丁经济专区开发集团有限公司”签订投资合同（**合同许可**从事该业务）。

4. **投资前审查 (2023年)：** 依据老挝《企业法》、《外国投资促进法》，通过磨丁招商局向老挝琅南塔省政府、磨丁经济特区管委会及国家计划投资部等部门提交完整项目材料（**获得审查通过**）。

5. **企业设立 (2023年)：** 通过审查，成功获得老挝计划投资部及琅南塔经济特区管委会颁发的企业注册证及税务登记证（**证照包含**辅助生殖试管婴儿医疗服务、医院等6个项目）。

6. **试运营许可 (2024年)：** 获得磨丁经济特区管委会及招商局许可，开展辅助生殖及干细胞医疗业务试运营（**明确许可**）。

7. **问题暴露 (2024年10月-2025年5月)：** 截至2025年5月，磨丁招商局已引进13家中外辅助生殖/干细胞医院。老挝公安部于2024年10月和2025年4月两次突击查封其中5家医院，没收设备、拘押人员等（太诊国际医院未被查封）。此事暴露出磨丁存在严重的招商问题（**此时才知相关业务实际被禁止**）。

8. **运营受阻 (2025年)：** 经核实，虽然太诊医院项目已获投资批准且证照齐全，但依据老挝《医疗法》、《私立医院设立指导意见》及《代孕和堕胎管理协议》，卫生部禁止私立医院从事辅助生殖技术，拒绝批准相关医疗许可（**最终确认无法运营**）。

为维护老挝的国际投资环境声誉，我于今年1月致信联合国驻老挝协调员Bakhodir Burkhanov先生。他两次回信表示已将此事转呈老挝中央政府相关部门。同时，我也积极与中国驻老挝大使馆、中国商务部、外交部、云南省人民政府、上海市人民政府等十余个部门沟通，寻求协调解决。

2025年5月20日，在中国驻老挝大使馆安排下，我拜会了老挝卫生部医疗康复司司长Khamsay先生。他对我的遭遇表示同情，但明确指出：尽管太诊医院已通过投资准入审查并获得包含辅助生殖服务内容的合法企业注册证和税务登记证，但根据卫生部现行法规，他无法为作为私立医院的我们颁发辅助生殖技术医疗许可。

尊敬的主席阁下，从我的履历中您可以看到，我并非纯粹的商人，而是一名生物医疗科技工作者。我怀着推动中老生物医疗技术交流合作的最真诚愿望来到老挝投资。我深信，老挝正经历着类似中国改革开放初期的阶段，许多有益于技术进步和国民福祉的新生事物，其初始阶段难免受到质疑。但在您卓越的智慧和远见卓识领导下，任何困难都能被克服。在您的指引下，老挝政府和人民每天都在实现技术与组织的革新进步。您是照亮老挝发展道路的太阳。

我恳切地请求您对此事予以关注和支持。我渴望能继续留在老挝这片美丽的土地上，在生物医疗技术领域为老挝的发展贡献力量。愿老中友谊万古长青。

期待您的回复。衷心感谢您拨冗阅读此信。

此致

崇高的敬意！

您真诚的国际合作友人

董寿伟

2025年7月7日

06/06/2025

中文内容往下拉 / ເລື່ອນລົງເພື່ອເບິ່ງເນື້ອໃນພາສາລາວ
The Ministry of Planning and Investment of Laos, the Planning and Investment Department of Luang Namtha Province of Laos, and the Management Committee of the Luang Namtha Special Economic Zone of Laos directly participated in the investment fraud of our project. First, Khonethong LEOUNGKHAMMA, director of the Management Committee of the Luang Namtha Special Economic Zone of Laos, issued a "fake" certificate of our low-cost assisted reproductive hospital as bait. In 2023, after we officially signed a site lease contract with Laos Boten Special Economic Zone Development Group Co., Ltd. to engage in assisted reproductive and stem cell medical hospital project, we submitted the lease contract, project business investment plan and feasibility report, overseas investor resumes and other materials to the relevant departments of the Lao government through the Laos Boten Special Economic Zone Investment Bureau. The above materials all made it clear that the purpose of our investment in Laos is to engage in assisted reproductive stem cell specialty hospital projects. The Lao government (Ministry of Planning and Investment of Laos, Department of Planning and Investment of Luang Namtha Province of Laos, Management Committee of Boten Special Economic Zone of Luang Namtha Province of Laos), as the government departments and offices of Laos, knew that the Lao Ministry of Health had a ban on private hospitals engaging in assisted reproductive medicine, and no private hospital projects had been approved for IVF assisted reproductive medicine nationwide, but still cooperated with Lao Boten Special Economic Zone Development Group Co., Ltd. to pass the project review of our investment in assisted reproductive hospital in Laos, and issued us a enterprise registration certificate and tax registration certificate with the letters of the Ministry of Planning and Investment of Laos and the Management Committee of Luang Namtha Province of Laos, with 6 allowed project business items such as assisted reproductive IVF medical services, hospitals, public health services, and clinical medical research. In other words, it clarified the legality of our investment in the establishment of an assisted reproductive hospital in Laos, but this conflicts with the law of the Lao Ministry of Health prohibiting private hospitals from engaging in assisted reproductive IVF medicine in Laos in accordance with the Lao Medical Law, Guidance on the Establishment of Private Hospitals, and Regulations on Surrogacy and Abortion. Therefore, the behavior of the Lao government is a government-induced investment fraud.
ກະຊວງແຜນການ ແລະ ການລົງທຶນຂອງລາວ, ພະແນກແຜນການ ແລະ ການລົງທຶນ ແຂວງຫຼວງນ້ຳທາ ຂອງລາວ, ແລະ ຄະນະບໍລິຫານງານເຂດເສດຖະກິດພິເສດຫຼວງນ້ຳທາຂອງລາວ ໄດ້ເຂົ້າຮ່ວມໂດຍກົງ ໃນການສໍ້ໂກງການລົງທຶນຂອງໂຄງການພວກເຮົາ. ກ່ອນອື່ນ, ທ່ານ ຄອນທອງ ເລືອງຄຳມາ, ຫົວໜ້າຄະນະຄຸ້ມຄອງເຂດເສດຖະກິດພິເສດຫຼວງນ້ຳທາ ຂອງລາວ ໄດ້ອອກໃບຢັ້ງຢືນ “ປອມ” ຂອງໂຮງໝໍຊ່ວຍການຈະເລີນພັນ ລາຄາຖືກ ຂອງພວກເຮົາເປັນເຫຍື່ອ. ໃນປີ 2023, ພາຍຫຼັງທີ່ໄດ້ເຊັນສັນຍາເຊົ່າຢ່າງເປັນທາງການກັບກຸ່ມບໍລິສັດພັດທະນາເຂດເສດຖະກິດພິເສດລາວບໍ່ເຕັນ ຈຳກັດ ເພື່ອດໍາເນີນໂຄງການໂຮງໝໍຊ່ວຍການຈະເລີນພັນ ແລະ ເຊລຈຸລັງປອດ, ພວກເຮົາໄດ້ສົ່ງສັນຍາເຊົ່າ, ແຜນການລົງທຶນໂຄງການ ແລະ ບົດລາຍງານຄວາມເປັນໄປໄດ້, ຊີວະປະຫວັດຫຍໍ້ຂອງຜູ້ລົງທຶນຈາກຕ່າງປະເທດ ແລະ ເອກະສານອື່ນໆໃຫ້ພະແນກການທີ່ກ່ຽວຂ້ອງຂອງລັດຖະບານລາວ ຜ່ານຫ້ອງການເຂດເສດຖະກິດພິເສດລາວ ບໍ່ເຕັນ. ເອກະສານທີ່ກ່າວມາຂ້າງເທິງນັ້ນ ລ້ວນແລ້ວແຕ່ເຮັດໃຫ້ເຫັນໄດ້ຊັດເຈນວ່າ ຈຸດປະສົງຂອງການລົງທຶນຂອງພວກເຮົາໃນລາວ ແມ່ນເພື່ອເຂົ້າຮ່ວມໂຄງການໂຮງໝໍພິເສດສະເພາະຂອງຈຸລັງການຈະເລີນພັນ. ລັດຖະບານລາວ (ກະຊວງແຜນການ ແລະ ການລົງທຶນຂອງລາວ, ພະແນກແຜນການ ແລະ ການລົງທຶນແຂວງຫຼວງນ້ຳທາ, ຄະນະຄຸ້ມຄອງເຂດເສດຖະກິດພິເສດບໍ່ເຕັນ ແຂວງຫຼວງນ້ຳທາ), ທັງເປັນພະແນກການ ແລະ ຫ້ອງການຕ່າງໆຂອງລາວ, ໃຫ້ຮູ້ວ່າ: ກະຊວງສາທາລະນະສຸກລາວມີຂໍ້ຫ້າມບໍ່ໃຫ້ໂຮງໝໍເອກະຊົນເຮັດຢາຊ່ວຍຈະເລີນພັນ, ແລະຍັງບໍ່ມີໂຄງການໂຮງໝໍເອກະຊົນທີ່ໄດ້ຮັບການອະນຸມັດເພື່ອສົ່ງເສີມການລ້ຽງລູກດ້ວຍນົມແມ່. ຮ່ວມກັບກຸ່ມບໍລິສັດພັດທະນາເຂດເສດຖະກິດພິເສດລາວບໍ່ເຕັນ ຈຳກັດ ເພື່ອຜ່ານບົດສະຫຼຸບໂຄງການລົງທຶນໃນໂຮງໝໍຊ່ວຍການຈະເລີນພັນໃນລາວ ແລະ ອອກໃບທະບຽນວິສາຫະກິດ ແລະ ໃບທະບຽນອາກອນ ພ້ອມດ້ວຍຈົດໝາຍຂອງກະຊວງແຜນການ ແລະ ການລົງທຶນ ແລະ ຄະນະບໍລິຫານງານແຂວງຫຼວງນ້ຳທາ ຂອງລາວ, ເຊິ່ງມີ 6 ທຸລະກິດໂຄງການທີ່ອະນຸຍາດເຊັ່ນ: ການບໍລິການທາງການແພດຊ່ວຍລະບົບ IVF ການຈະເລີນພັນ, ໂຮງໝໍ ແລະ ໂຮງໝໍ. ເວົ້າອີກຢ່າງໜຶ່ງ, ມັນຊີ້ແຈງເຖິງຄວາມຖືກຕ້ອງທາງດ້ານກົດໝາຍຂອງການລົງທຶນໃນການສ້າງໂຮງໝໍຊ່ວຍຈະເລີນພັນໃນລາວ, ແຕ່ອັນນີ້ຂັດກັບກົດໝາຍຂອງກະຊວງສາທາລະນະສຸກຂອງລາວທີ່ຫ້າມບໍ່ໃຫ້ໂຮງໝໍເອກະຊົນເຮັດຢາຊ່ວຍການຈະເລີນພັນໃນລາວຕາມກົດໝາຍການແພດຂອງລາວ, ຄຳແນະນຳກ່ຽວກັບການສ້າງຕັ້ງໂຮງໝໍເອກະຊົນ ແລະ ລະບຽບການກ່ຽວກັບການຖືພາ. ສະນັ້ນ, ພຶດຕິກຳຂອງ ຣັຖບານລາວ ເປັນການສໍ້ໂກງ ການລົງທຶນ ຂອງຣັຖບານ.
老挝计划投资部、老挝琅南塔省计划投资厅、老挝琅南塔省磨丁经济特区管委会直接参与了我们项目的招商欺诈。首先老挝琅南塔省经济特区管委会主任Khonethong LEOUNGKHAMMA签发发了我们代价不高的辅助生殖医院的“假”证做诱饵，在2023年我们正式与老挝磨丁经济专区开发集团有限公司签约从事辅助生殖、干细胞医疗医院项目场地租赁合同后，我们通过老挝磨丁经济特区招商局向老挝政府有关部门提交了租赁合同，和项目商业投资计划书及可行性报道，境外投资者简历等材料，以上材料都明确了我们在老挝投资的目的是从事辅助生殖干细胞专科医院项目。老挝政府（老挝计划投资部、老挝琅南塔省计划投资厅、老挝琅南塔省磨丁经济特区管委会）作为老挝国家的政府部门，在明知老挝卫生部在私人医院从事辅助生殖医疗存在禁令，且全国范围内尚未在试管婴儿辅助生殖医疗上批准过私人医院项目，但还是配合老挝磨丁经济专区开发集团有限公司通过了我们在老挝投资辅助生殖医院的项目审查，给我们颁发了带老挝计划投资部和老挝琅南塔省经济特区管委会抬头的带有辅助生殖试管婴儿医疗服务、医院、公共卫生服务、临床医学研究等6个项目经营项目的企业注册登记证和税务登记证，也就是明确了我们在老挝投资设立辅助生殖医院的合法性，但这与老挝卫生部依据老挝《医疗法》、《私立医院设立指导》和《代孕和堕胎管理条例》禁止私立医院在老挝从事辅助生殖试管婴儿医疗的法律相冲突。因此，老挝政府的行为是政府性招商诈骗行为。

06/06/2025

ສະມາຊິກ CPPCC ເມືອງຊຽງໄຮ້ Putuo, ສະມາຊິກຄະນະກໍາມະການປະຕິວັດນະຄອນຊຽງໄຮ້ຂອງ Kuomintang, ສະມາຊິກຂອງສະມາຄົມສົ່ງເສີມການຮ່ວມມືພາກໃຕ້ - ໃຕ້ (Shanghai) ພາຍໃຕ້ການກະຊວງການຕ່າງປະເທດຈີນ, ຜູ້ຈັດການທົ່ວໄປຂອງຈີນ-Israel Huida (Shanghai) Biotechnology Co., Ltd., ປະທານບໍລິຫານຂອງສະຫະພັນ Boccient ສາກົນຈີນ, ຫົວຫນ້າໂຄງການການແພດລາວແລະບໍລິສັດການແພດ Bocc. ໂຮງໝໍ, ທ່ານດຣ ດົ່ງຊູ້ເວຍ [ເບິ່ງສາລານຸກົມ Baidu ຂອງ D**g Shouwei] ໄດ້ດຳເນີນກອງປະຊຸມວຽກງານເພື່ອຢັ້ງຢືນ ແລະ ກວດກາເນື້ອໃນຂອງກອງປະຊຸມລະຫວ່າງລັດຖະບານ 6 ຝ່າຍ ນະຄອນຄຸນໝິງ ໃນວັນທີ 8 ເມສາ 2025 ທີ່ເຂດເສດຖະກິດພິເສດ ລາວບໍ່ເຕັນ ແລະ ນະຄອນຫຼວງວຽງຈັນ ແຕ່ວັນທີ 11 ຫາ 25 ພຶດສະພາ 2025.

ກ່ຽວກັບການສໍ້ໂກງການລົງທຶນໂຄງການໂຮງໝໍສາກົນ ລາວໂບເທນ ປາຊີລິນິກ ໄດ້ພົບເຫັນ ແລະ ເກີດຂຶ້ນຈາກອົງການລົງທຶນເຂດເສດຖະກິດພິເສດລາວບໍ່ເຕັນ ຮ່ວມກັບລັດຖະບານລາວ ບໍ່ເຕັນ, ແຂວງຫຼວງນ້ຳທາ ແລະ ກົມແຜນການ ແລະ ການລົງທຶນແຫ່ງຊາດລາວ ເຊິ່ງເກີດຂຶ້ນຢູ່ເຂດການຮ່ວມມືຈີນ-ລາວໂມຮັນ-ບໍ່ເຕັນ ໂດຍການປະສານງານແລະຄຸ້ມຄອງໂດຍແຂວງຢຸນນານຂອງຈີນ, ແຂວງຫຼວງນ້ຳທາຂອງລາວໄປຢ້ຽມຢາມ. ກົມການລົງທຶນເຂດ, ຄະນະກຳມະການຄຸ້ມຄອງເຂດເສດຖະກິດພິເສດລາວບໍ່ທັນ, ສະຖານທູດຈີນປະຈຳລາວ, ກະຊວງສາທາລະນະສຸກລາວ, ຫ້ອງການປະສານງານອົງການສະຫະປະຊາຊາດປະຈຳລາວ, ບໍລິສັດທາງລົດໄຟລາວ-ຈີນຈຳກັດ, (

ເນື່ອງຈາກເວລາແລະຂໍ້ຈໍາກັດອື່ນໆ, ການສື່ສານບາງຢ່າງໄດ້ຖືກດໍາເນີນຜ່ານ WeChat, WhatsApp, ໂທລະສັບຫຼືອີເມລ໌.)

ອີງຕາມບົດບັນຍັດຂອງກົດໝາຍວ່າດ້ວຍວິສາຫະກິດລາວ ແລະ ກົດໝາຍວ່າດ້ວຍການສົ່ງເສີມການລົງທຶນຂອງຕ່າງປະເທດ, ນັກລົງທຶນຕ່າງປະເທດຕ້ອງສົ່ງແຜນການລົງທຶນ ຫຼື ບົດລາຍງານຄວາມເປັນໄປໄດ້ຂອງໂຄງການ, ຊີວະປະຫວັດຫຍໍ້ຂອງຜູ້ລົງທຶນຕ່າງປະເທດ ແລະ ເອກະສານການສະໝັກອື່ນໆໃຫ້ພະແນກແຜນການການລົງທຶນແຂວງ ແລະ ເທດສະບານຂອງສະຖານທີ່ໂຄງການເພື່ອກວດກາຄືນກ່ອນການລົງທຶນໃນລາວ. ຖ້າໂຄງການລົງທຶນທີ່ນຳໃຊ້ເຂົ້າໃນການດຳເນີນທຸລະກິດແມ່ນປະກອບດ້ວຍອຸດສາຫະກຳທີ່ຖືກຈຳກັດ ແລະ ຄວບຄຸມໂດຍລັດຂອງລາວ ແລະ ບໍ່ຢູ່ໃນອຳນາດການອະນຸມັດຂອງອຳນາດການປົກຄອງຂັ້ນແຂວງ ແລະ ເທດສະບານ, ລັດຖະບານແຂວງ ແລະ ເທດສະບານຈະຕ້ອງນຳໃຊ້ກັບພະແນກແຜນການ ແລະ ການລົງທຶນຂອງລັດ ແລະ ພະແນກການທີ່ກ່ຽວຂ້ອງ. ນັກລົງທຶນຕ່າງປະເທດທີ່ປະຕິບັດຕາມຂໍ້ກໍານົດຂອງກົດໝາຍຈະຕ້ອງໄດ້ຮັບໃບອະນຸຍາດລົງທຶນຕ່າງປະເທດ, ໃບທະບຽນວິສາຫະກິດ ແລະ ໃບທະບຽນອາກອນພ້ອມໆກັນ ຈາກພະແນກສົ່ງເສີມ ແລະ ຄຸ້ມຄອງການລົງທຶນຂອງແຂວງ, ນະຄອນ ແລະ ພາກພື້ນທີ່ເຂົາເຈົ້າໄດ້ຮັບໃບອະນຸຍາດ. ຫຼັງຈາກນັ້ນ, ເຂົາເຈົ້າຈະຖືກຖືວ່າເປັນວິສາຫະກິດທີ່ຖືກສ້າງຕັ້ງຂື້ນຕາມກົດຫມາຍຂອງລາວ.

ຕາມຂໍ້ກຳນົດຂອງກົດໝາຍວ່າດ້ວຍວິສາຫະກິດລາວ, ຜູ້ທີ່ຕັ້ງໃຈດຳເນີນທຸລະກິດຢູ່ລາວຄວນຍື່ນຄຳຮ້ອງຂໍຂຶ້ນທະບຽນວິສາຫະກິດຕໍ່ອົງການລັດທີ່ກ່ຽວຂ້ອງຕາມລະບຽບການ. ພາຍຫຼັງໄດ້ຮັບໃບຮ້ອງຂໍຂຶ້ນທະບຽນວິສາຫະກິດແລ້ວ, ກົມທຸລະກິດຈະກວດກາເບິ່ງວ່າປະເພດທຸລະກິດທີ່ຈະຂຶ້ນທະບຽນເປັນບັນຊີການດຳເນີນງານທີ່ຄວບຄຸມຫຼືບໍ່. ຖ້າທຸລະກິດບໍ່ຢູ່ໃນບັນຊີລາຍຊື່ຄວບຄຸມ, ອໍານາດການລົງທະບຽນທຸລະກິດຂອງພະແນກການຄ້າຕ້ອງອອກໃບຢັ້ງຢືນການລົງທະບຽນວິສາຫະກິດພາຍໃນສິບວັນເຮັດວຽກນັບຈາກມື້ທີ່ໄດ້ຮັບຄໍາຮ້ອງຂໍ.

ຖ້າປະເພດທຸລະກິດທີ່ຮ້ອງຂໍຂຶ້ນທະບຽນເປັນບັນຊີທຸລະກິດຄວບຄຸມ, ພະແນກການຄ້າຕ້ອງຍື່ນຕໍ່ພະແນກທີ່ກ່ຽວຂ້ອງທັນທີ. ຍົກເວັ້ນບາງທຸລະກິດທີ່ຕ້ອງການຂະບວນການກວດກາດ້ານວິຊາການທີ່ຍາວນານ, ພະແນກທີ່ມີຄວາມສາມາດຈະພິຈາລະນາແລະຕອບສະຫນອງບໍ່ເກີນສິບມື້ເຮັດວຽກ. ຈາກນັ້ນ, ພະແນກການຄ້າຕ້ອງອອກໃບທະບຽນວິສາຫະກິດພາຍໃນ 3 ວັນເຮັດວຽກ.

ເກີດເຫດການສໍ້ໂກງການລົງທຶນຂອງໂຮງໝໍສາກົນລາວ Boten Paccilinic

ໄລຍະ

ຂັ້ນຕອນການສະໝັກເຂົ້າໂຮງໝໍສາກົນລາວ Boten Paccilinic

ວັນທີ

ມັນອະນຸຍາດໃຫ້ Paccilinic ໃຫ້ບໍລິການທາງການແພດຊ່ວຍການຈະເລີນພັນບໍ?

1

ກອງປະຊຸມສົ່ງເສີມການລົງທຶນ

ກອງປະຊຸມສົ່ງເສີມການລົງທຶນຈີນແຂວງຢຸນນານ Shanghai;

ຄູ່ມືສົ່ງເສີມການລົງທຶນຂອງລັດຖະບານແຂວງຢຸນນານຈີນ;

2022

ແມ່ນແລ້ວ

2

ໄດ້ໄປຢ້ຽມຢາມກໍລະນີທີ່ໂຮງຫມໍ

ໂຮງໝໍຊ່ຽວຊານດ້ານການສືບພັນທາງພັນທຸກໍາຂອງ Boten Laos, ເປີດໃນປີ 2019;

Boten Reproduction Center ໄດ້ມາໂດຍບໍລິສັດຈົດທະບຽນ HK ໃນປີ 2020;

2023

2023

ເປີດ, ແມ່ນແລ້ວ

ເປີດ, ແມ່ນແລ້ວ

3

ເຊັນສັນຍາທຸລະກິດ

ສັນຍາຂອງກຸ່ມບໍລິສັດພັດທະນາເຂດເສດຖະກິດບໍ່ເຕັນຂອງລາວຈຳກັດທີ່ເປັນບໍລິສັດຍ່ອຍຂອງກຸ່ມບໍລິສັດຈີນຢຸນນານໄຫເຊັງ.

2023

ແມ່ນແລ້ວ

4

Laos Pre-Investment Review

ອີງຕາມກົດໝາຍວ່າດ້ວຍວິສາຫະກິດລາວ ແລະ ກົດໝາຍສົ່ງເສີມການລົງທຶນຈາກຕ່າງປະເທດ, ຜ່ານຫ້ອງການສົ່ງເສີມການລົງທຶນບໍ່ເຕັນ ໄດ້ສົ່ງບົດລາຍງານຄວາມເປັນໄປໄດ້ຂອງໂຄງການລົງທຶນໂຄງການຊ່ວຍການຈະເລີນພັນ ແລະ ໂຮງ ໝໍ stem cell, ຊີວະປະຫວັດຫຍໍ້ຂອງຜູ້ລົງທຶນຕ່າງປະເທດ, ສັນຍາທຶນຮອນຂອງວິສາຫະກິດລົງທຶນ ແລະ ເອກະສານການສະເໜີອື່ນໆໃຫ້ພະແນກການທີ່ກ່ຽວຂ້ອງຂອງລັດຖະບານລາວ (ຄະນະບໍລິຫານງານເຂດເສດຖະກິດພິເສດລາວ ຫຼວງນ້ຳທາ, ລັດຖະບານ ແລະ ອຳນາດການປົກຄອງແຂວງ. ການລົງທຶນ, ແລະອື່ນໆ).

2023

ແມ່ນແລ້ວ

5

ການສ້າງຕັ້ງວິສາຫະກິດ

ຜ່ານການກວດກາໂຄງການລົງທຶນຂອງນັກລົງທຶນຕ່າງປະເທດ ແລະ ໄດ້ຮັບໃບທະບຽນວິສາຫະກິດ ແລະ ໃບທະບຽນອາກອນ ຈໍານວນ 6 ໂຄງການ ລວມມີ ການບໍລິການແພດຊ່ວຍການຈະເລີນພັນ, ໂຮງໝໍ, ການບໍລິການສາທາລະນະສຸກ, ການຄົ້ນຄວ້າທາງດ້ານການແພດ ແລະ ອື່ນໆ ທີ່ກະຊວງແຜນການ ແລະ ການລົງທຶນຂອງລາວ ແລະ ຄະນະບໍລິຫານງານເຂດເສດຖະກິດພິເສດແຂວງຫຼວງນໍ້າທາ ອອກໃຫ້.

2023

ແມ່ນແລ້ວ

6

ການທົດລອງ

ໄດ້ຮັບອະນຸຍາດຈາກຄະນະກຳມະການຄຸ້ມຄອງເຂດເສດຖະກິດພິເສດບໍ່ແຮ່ ແຂວງຫຼວງນ້ຳທາ ລັດຖະບານ ແລະ ອົງການສົ່ງເສີມການລົງທຶນເຂດເສດຖະກິດພິເສດບໍ່ເຕັນ ເພື່ອດຳເນີນການກໍ່ສ້າງໂຮງໝໍໃນການຊ່ວຍເຫຼືອເຕັກໂນໂລຊີທໍ່ທົດສອບການສືບພັນເດັກ ແລະ ການບໍລິການການແພດດ້ວຍຈຸລັງລຳຕົ້ນ.

2024

ແມ່ນແລ້ວ

7

ການສໍ້ໂກງການລົງທຶນຂອງ Boten ເປີດເຜີຍ

ມາຮອດເດືອນພຶດສະພາ 2025, ສຳນັກງານສົ່ງເສີມການລົງທຶນຂອງລາວໄດ້ລົງນາມໃນໂຮງໝໍ 13 ແຫ່ງທີ່ໃຫ້ການຊ່ວຍເຫຼືອດ້ານການແຜ່ພັນແລະຢາເມັດຈຸລັງໂດຍມີນັກລົງທຶນຈາກຈີນ, ອາເມລິກາແລະປະເທດອື່ນໆ. ກະຊວງ ປທສ ລາວ ບຸກເຂົ້າກວດຄົ້ນ ແລະປິດໂຮງໝໍ 5 ແຫ່ງ ຢູ່ເມືອງບຸນເໜືອ 2 ຄັ້ງ ໃນເດືອນ ຕຸລາ 2024 ແລະ ເດືອນເມສາ ປີ 2025, ປົດອຸປະກອນໂຮງໝໍທັງໝົດ, ພະນັກງານ ຈັບຕົວ ແລະ ຮຽກຮ້ອງຄ່າໄຖ່ສູງ ຈາກພະນັກງານຈີນ (ຂ່າວລືວ່າ 400,000 RMB/ຄົນຈີນ). (ໂຮງໝໍສາກົນ Pacclinic ບໍ່ແມ່ນຢູ່ໃນນັ້ນ)

ໃນຈຸດນີ້, ເຫດການສໍ້ໂກງການລົງທຶນຂອງກຸ່ມບໍລິສັດຂະໜາດໃຫຍ່ໂດຍລັດຖະບານລາວບໍ່ເຕັນໄດ້ເປີດເຜີຍ.

2024

2025

ບໍ່

8

ຢຸດຊົ່ວຄາວ

ໂດຍການທົບທວນຄືນໃບຢັ້ງຢືນ Paccilinic ທີ່ໄດ້ຮັບ, ກະຊວງສາທາລະນະສຸກລາວໄດ້ຮັບຮູ້

ພາກສ່ວນກ່ຽວຂ້ອງຂອງລັດຖະບານລາວ ໄດ້ອະນຸມັດການລົງທຶນທີ່ອະນຸຍາດໃຫ້

ໂຄງການໂຮງໝໍນາໆຊາດ Boten Paccilinic ຂອງລາວ ເພື່ອສະໜອງທໍ່ທົດລອງການຈະເລີນພັນຂອງເດັກ ແລະ ການບໍລິການປິ່ນປົວດ້ວຍຈຸລັງລໍາຕົ້ນ. ຂະນະດຽວກັນ, ການປະຕິບັດທາງດ້ານກົດໝາຍຂອງໂຮງໝໍດັ່ງກ່າວ ຮຽກຮ້ອງໃຫ້ກະຊວງສາທາລະນະສຸກລາວ ສະເໜີຂໍໃບອະນຸຍາດສ້າງຕັ້ງໂຮງໝໍສຳລັບທຸລະກິດທີ່ກ່ຽວຂ້ອງຂ້າງເທິງ. ຢ່າງໃດກໍ່ຕາມ, ອີງຕາມ "ກົດຫມາຍວ່າດ້ວຍທາງການແພດ", "ຄໍາແນະນໍາກ່ຽວກັບການສ້າງຕັ້ງໂຮງຫມໍເອກະຊົນ" ແລະ "ສັນຍາການຖືພາແລະການທໍາແທ້ງ",

ກະຊວງ ສາທາຣະນະສຸຂລາວ ຫ້າມໂຮງ ໝໍເອກກະຊົນ ປະຕິບັດ ເທັກໂນໂລຍີ IVF ການຈະເລີນພັນ ແບບຊ່ອຍເຫລືອ ແລະ ປະຕິເສດ ການອະນຸມັດ ໃບອະນຸຍາດ ສ້າງຕັ້ງໂຮງໝໍ ສໍາລັບ ທຸຣະກິດ ທີ່ກ່ຽວຂ້ອງ.

2025

ບໍ່

ໃນປັດຈຸບັນ, ຄວາມຂັດແຍ້ງໃນການຈັດຕັ້ງປະຕິບັດກົດໝາຍ ແລະ ນະໂຍບາຍລະຫວ່າງລັດຖະບານຕ່າງໆໃນລາວ ອາດເຮັດໃຫ້ເກີດຄວາມເສຍຫາຍຢ່າງໃຫຍ່ຫຼວງຕໍ່ການລົງທຶນໃນໂຄງການໂຮງໝໍສາກົນລາວ Boten Paccilinic. ຖ້ານະໂຍບາຍທາງດ້ານກົດໝາຍທີ່ອີງໃສ່ກະຊວງສາທາລະນະສຸກຂອງລາວຖືກນຳໃຊ້ເປັນການຕັດສິນໃຈຂັ້ນສຸດທ້າຍ, ສະຖານທີ່ລົງທຶນໃນໂຄງການໂຮງໝໍນາໆຊາດ Boten Paccilinic ຂອງລາວຈະບໍ່ມີອີກຕໍ່ໄປ. ນອກຈາກນີ້, ການສໍ້ໂກງການລົງທຶນຂະໜາດໃຫຍ່ທີ່ພົວພັນກັບໂຄງການລົງທຶນຢູ່ຕ່າງປະເທດຂອງໂຮງໝໍ 13 ແຫ່ງ (ຈີນ-ຈີນ) ໃນລາວ ກໍ່ຕ້ອງກ່ຽວຂ້ອງກັບການສໍ້ລາດບັງຫຼວງລະຫວ່າງກຸ່ມບໍລິສັດພັດທະນາເຂດເສດຖະກິດບໍ່ເຕັນ ແລະ ຄະນະກຳມະການຄຸ້ມຄອງເຂດເສດຖະກິດພິເສດບໍ່ເຕັນ ແຂວງຫຼວງນ້ຳທາ, ລັດຖະບານແຂວງຫຼວງນ້ຳທາ ແລະ ກະຊວງແຜນການ ແລະ ການລົງທຶນຂອງລາວ ໄດ້ສ້າງຄວາມເສຍຫາຍຢ່າງໜັກໜ່ວງ.

ຂະນະດຽວກັນ, ທ່ານດຣ ດົ່ງຊູ້ເວຍ ໄດ້ລາຍງານຕໍ່ອົງການຕ້ານການສໍ້ລາດບັງຫຼວງຂອງອົງການສະຫະປະຊາຊາດ (UNODC) ກ່ຽວກັບບັນຫາການສໍ້ລາດບັງຫຼວງທີ່ເກີດຂຶ້ນລະຫວ່າງລັດຖະບານລາວ ແລະ ລະຫວ່າງລັດຖະບານລາວ ກັບບັນດາວິສາຫະກິດທີ່ດໍາເນີນທຸລະກິດ Boten ທີ່ພົວພັນກັບການສໍ້ໂກງການລົງທຶນຂອງໂຮງໝໍນາໆຊາດ Boten Paccilinic ຂອງລາວ.

Pacclinic International Hospital

02/12/2025

05/10/2025

05/10/2025

21/09/2025

11/07/2025

06/06/2025

06/06/2025

Address

Opening Hours

Telephone

Website

Alerts

Contact The Practice

Shortcuts

Share

Category

Monday	08:00 - 18:00
Tuesday	08:00 - 18:00
Wednesday	08:00 - 18:00
Thursday	08:00 - 18:00
Friday	08:00 - 18:00
Saturday	08:00 - 18:00
Sunday	08:00 - 18:00